LGD-4033 (Ligandrol) is an orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM) that binds to the androgen receptor with a Ki value of 1 nM.1 In animal models,LGD-4033 (Ligandrol) displays robust selectivity for muscle versus prostate tissues, anabolic activity in the muscle, and anti-resorptive and anabolic activity in bone.1 LGD-4033 (Ligandrol) has been abused as a performance-enhancing drug and the identification of its in vitro metabolites has been described.2,3 This product is intended for research and forensic applications.
References:
1.Basaria, S., Collins, L., Dillon, E.L., et al.The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young menJ. Gerontol. A Biol. Sci. Med. Sci.68(1)87-95(2013)
2.Geldof, L., Pozo, O.J., Lootens, L., et al.In vitro metabolism study of a black market product containing SARM LGD-4033Drug Test Anal.9(2)168-178(2016)
3.Thevis, M., Lagojda, A., Kuehne, D., et al.Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the internet and identification of in vitro generated phase-I metabolites for human sports drug testingRapid Commun Mass Spectrom.29(11)991-999(2015)